Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — Investor Conference Naples Banca Profilo 2025
27 slides from Arterra Bioscience Spa's conference presentation, Oct 2, 2025
Slide 1: Investor Conference Naples Banca Profilo
INVESTOR CONFERENCE NAPLES Banca Profilo OCTOBER 2nd, 2025
Slide 2: Index
INDEX TO P I C S • ARTERRA AT GLANCE • MARKET CONSOLIDATION • FINANCIALS
Slide 3: People Speaking Today
PEOPLE SPEAKING TODAY M. GABRIELLA COLUCCI GUALTIERO IOIMO Founder, President and CEO CFO and Investor Relations Manager
Slide 4: Arterra Bioscience - Innovative SME
ARTERRA BIOSCIENCE - Innovative SME Arterra Bioscience is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various i
Slide 5: Arterra & Vitalab Team
ARTERRA & VITALAB TEAM 33 12 PhD 13 Chem Ing 2 MSc 11 Tech 11 Administration 6 1,600 sqm PhD Students 2
Slide 6: Our Facilities
OUR FACILITIES ❖ Chemistry Lab ❖ Plant Cell Culture Lab ❖ Microbiology Lab ❖ New ❖ Molecular & Cell Biol. Lab ❖ Histology & Microscopy Lab ❖ Process Lab ❖ Production Lab ❖ Plant Cells Culture Growing Facility ❖ MicroAlgae Growing Facility ❖ Plant Growing Facility ❖ Lactobacillus & Agrobacterium Grow
Slide 7: Arterra & Vitalab Team
ARTERRA & VITALAB TEAM M. GABRIELLA COLUCCI GIUSEPPE FERRANTE ANNALISA TITO CEO COO Cell & Mol Biol. Director VINCENZO FOGLIANO MARIDA BIMONTE CSO Grant & IP Director
Slide 8: Company Organization
COMPANY ORGANIZATION President & CEO Gabriella Accounting Financial Management Assistant Gualtiero Investor Relations Alexandra Quality Control Scientific Coordinator Luigi Vincenzo Vitalab: Marketing and Regulatory Annalisa Production Director Giuseppe Grant & IP Office Director Marida Cell Culture
Slide 9: From the Idea to the Product
FROM THE IDEA TO THE PRODUCT Microbiology Chemistry Scientific Breakthrough Biochemistry Genetic Engineering Plants New Tech. Skin Biology THINK TANK TEAM TTU Insight and Feasibility of Ideas THINK TANK RESEARCH UNITS Management Team Approval INNOVATION TEAM IU INNOVATION RESEARCH UNITS From Idea to
Slide 10: Certifications
CERTIFICATIONS Ne EF/CI oO) Azienda certificata da ClimatePartner climate-id.com/RUPASF 2023 ecovadis [Sustainability Rating m ArterraBioscience
Slide 11: Arterra Position in Relevant Markets
ARTERRA POSITION IN RELEVANT MARKETS CONSUMER COSMETICS BEAUTY COSMETICS Skin Care, Make-Up, Personal Care & Hair Care Professional Cosmetic Products for topical applications in consolidated market through Intercos & Vitalab. Aestetic Medicine. New segment of a known market. Ingredients for topical
Slide 12: Sources for Active Ingredient Discovery & Development
SOURCES FOR ACTIVE INGREDIENT DISCOVERY & DEVELOPMENT BIOENGINEERING BASED 4 New Proprietary Strains of Lactobacillus BIOTECH BASED HIGH QUALITY EXTRACTS Plant Cell Culture MicroAlgae Wild Grown Plants Coltivated Mashroom (TCM) PATENT ON GENETIC ELEMENTS for Up Cycling Agricultural Waste Recombinant
Slide 13: Extraction Procedure
EXTRACTION PROCEDURE HYDROXYPROLINE RICH MULTIPEPTIDES Patent: WO 2007/104489 Gabriella Colucci, Fabio Apone, Maarten J. Chrispeels Method for the preparation of a NEWLY INTRODUCED TRADITIONAL composition based on 4-hydroxyproline IN HOUSE TECHNOLOGY J. Biotechnol., 145(4): 367-376 (2010). A mixture
Slide 14: Efficacy Evaluation Platform
EFFICACY EVALUATION PLATFORM IN VITRO MOLECULAR EX-VIVO ASSAY SKIN PENETRATION BIOLOGY & CELL BIOLOGY 29 assays Franz cells using 146 assays covering 10 skincare claims Strat-M membrane covering 26 skincare claims to follow the penetration FOR HAIRCARE 20 assays covering 3 haircare claims
Slide 15: Innovation in Cosmetic
INNOVATION IN COSMETIC CONSOLIDATED SEGMENT: SKINCARE & MAKE-UP & HAIRCARE 2024/2025 2024 2025 1. Tito A. et All - Skin rejuvenating properties of a powerful blend of Gardenia jasminoides peptides and flavonoids. 1. Vitale A., et All In vitro cellular model systems provide a promising 2. HPC Today,
Slide 16: Innovation in Cosmetic - Scientific Meetings
INNOVATION IN COSMETIC SCIENTIFIC MEETINGS 2024 2025 1. 8th international conference on microbial diversity. 23-26 september 2025. 1. 3rd International Summer School on Science based formulation, 1-3 July Martina Parziale : Development of probiotics and post-biotics for the 2024. Fiorella Nugnes mod
Slide 17: Innovation in Cosmetic - Patents
INNOVATION IN COSMETIC 2024/2025 Patents filed 2025 Patent examinations • Domanda di brevetto internazionale PCT/EP2024/074175: Use of plant- • Domanda di brevetto italiano n.102023000017877: Uso di estratti di derived extracts forhair growth stimulation and cosmetic or origine vegetale per la stimo
Slide 18: New Catalogue Products on the Market
INNOVATION IN COSMETIC 2024/2025 - 6 NEW catalogue products on the market Vita PeptiBloom Vita NiaCeraMine PlantExo Vita Peonia suffructicosa Hyssopus Officinalis plant cell cultures Exosome-based active ingredient plant cell cultures from Plantago lanceolata plant cell cultures NC75 Vita TechCollag
Slide 19: 2025 Exclusive Development For
INNOVATION IN COSMETIC 2025 EXCLUSIVE DEVELOPMENT FOR: n. 3 Exclusive Active Ingredients n. 1 Exclusive Active Ingredients n. 1 Exclusive Active Ingredients
Slide 20: Regulatory Achievements
REGULATORY ACHIEVEMENTS China State Council released the final version of CSAR on 01 January 2021 and replaced the existing Cosmetics Hygiene Supervision Regulations China’s new cosmetics regulation include many changes: ▪ New cosmetic definitions, scope and classifications ▪ Management of new cosme
Slide 21: Financials
FINANCIALS
Slide 22: Economic Results as of June 30, 2025
32,15% ECONOMIC RESULTS AS OF JUNE 30, 2025 VALUE OF PRODUCTION (€/000) EBITDA (€/000) NET INCOME (€/000) 3.142 22,3% 21% 633 17% 11,7% 2.319 37,6% 34,5% 2.120 309 1.085 659 1.181,31 2.572 517 2.251 1.593 249 486,33 366,12 -132 -241 -64 S1 2023 S1 2023 S1 2024 S1 2025 S1 2024 S1 2025 Changes in fini
Slide 23: No Debt / Equity
NO DEBT / EQUITY NET DEBT (€/000) EQUITY (€/000) 11.661 S1 2023 S1 2024 S1 2025 Cash and Cash Equivalents (4.337) (3.427) (3.442) 10.603 Current Financial Receivables - - - 10.050 Financial assets other than891 fixed 1.823 assets (1.201) (2.472) (2.573) Current Financial Debt 136 43 49 Current Net D
Slide 24: Economic Results as of December 31, 2024
32,15% ECONOMIC RESULTS AS OF DECEMBER 31, 2024 VALUE OF PRODUCTION (€/000) EBITDA (€/000) NET INCOME (€/000) 2500 40,2% 26,7% 5.303 5.266 25,4% 4.951 35 2.133 1.414 498 32,5% 1.337 231 2000 21,7% 1.058 32,1% 1.712 1.076 1.242 1.416 1.591 1500 1000 4.173 3.564 3.304 500 2022 2023 2024 0 2022 2023 20
Slide 25: No Debt / Equity
NO DEBT / EQUITY NET DEBT (€/000) EQUITY (€/000) 11.423 2022 2023 2024 10.751 Cash and Cash Equivalents (4.393) (3.686) (3.343) 10.467 Current Financial Receivables - - - Financial assets other than891 fixed 1.823 assets (1.598) Current Financial Debt 174 86 96 Current Net Debt (5.817) (3.599) (3.24
Slide 26: Revenue Comparison - H1 2025 vs H1 2024
REVENUE COMPARISON - H1 2025 vs H1 2024 S1 2025-S1 2024 S1 2025 vs S1 2024 3.500,00 3.142,01 Total turnover increased by 35.5% compared to the first semester of 3.000,00 35% 2.572,17 2024. 14% 2.500,00 2.250,70 2.318,46 The main driver of this growth was the sale of cosmetic raw materials, which ros
Slide 27: Thank You
INVESTOR CONFERENCE NAPLES Banca Profilo THANK YOU
Arterra Bioscience — Investor Conference Naples Banca Profilo 2025 on 6ix